Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Erectile Dysfunction, and Phosphodiesterase-5 Inhibitors

Overview

Journal Rev Urol

Date 2006 Sep 21

PMID 16985592

Citations 4

Authors

Claus G Roehrborn

Affiliations

Soon will be listed here.

Abstract

Many patients who present to their healthcare provider with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will also have erectile dysfunction (ED), and vice versa. Although alpha-adrenergic receptor blockers and 5-alpha-reductase inhibitors are highly effective in treating BPH-associated LUTS, these agents have sexual adverse effects that cause many men to discontinue therapy. The discovery of nitric oxide as a major factor in the mechanism of erection has led to the development of new drugs for ED, including the phosphodiesterase (PDE) inhibitors. Preliminary data support the theory that inhibition of PDE isoenzymes in the prostate may improve LUTS due to BPH through relaxation of prostatic smooth muscle. Further studies of PDE inhibitors in men with ED and BPH-associated LUTS are indicated.

Citing Articles

Self-Assessed Benefits of a Prostate Health Formulation on Nocturia in Healthy Males With Mild Lower Urinary Tract Symptoms: An Open Label Study.

Hirsh S, Pons M, Joyal S, Swick A Glob Adv Health Med. 2020; 9:2164956120973639.

PMID: 33294303 PMC: 7705803. DOI: 10.1177/2164956120973639.

Erectile dysfunction in the elderly: an old widespread issue with novel treatment perspectives.

Gareri P, Castagna A, Francomano D, Cerminara G, De Fazio P Int J Endocrinol. 2014; 2014:878670.

PMID: 24744785 PMC: 3976909. DOI: 10.1155/2014/878670.

Lower urinary tract symptoms (LUTS) as a risk factor for depressive symptoms in elderly men: results from a large prospective study in Southern Chinese men.

Chung R, Leung J, Chan D, Woo J, Wong C, Wong S PLoS One. 2013; 8(9):e76017.

PMID: 24098757 PMC: 3786898. DOI: 10.1371/journal.pone.0076017.

Measurement of benign prostatic hyperplasia treatment effects on male sexual function.

Skolarus T, Wei J Int J Impot Res. 2009; 21(5):267-74.

PMID: 19536125 PMC: 2862344. DOI: 10.1038/ijir.2009.26.

References

Kirby R, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary M . Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003; 61(1):119-26. DOI: 10.1016/s0090-4295(02)02114-3. View

Macfarlane G, Botto H, Sagnier P, Teillac P, Richard F, Boyle P . The relationship between sexual life and urinary condition in the French community. J Clin Epidemiol. 1996; 49(10):1171-6. DOI: 10.1016/0895-4356(96)00213-2. View

Takeda M, Tang R, Shapiro E, Burnett A, Lepor H . Effects of nitric oxide on human and canine prostates. Urology. 1995; 45(3):440-6. DOI: 10.1016/S0090-4295(99)80013-2. View

Feldman H, Goldstein I, Hatzichristou D, Krane R, McKinlay J . Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994; 151(1):54-61. DOI: 10.1016/s0022-5347(17)34871-1. View

Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S . Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci U S A. 2000; 97(7):3702-7. PMC: 16303. DOI: 10.1073/pnas.97.7.3702. View

Sairam K, Kulinskaya E, McNicholas T, Boustead G, Hanbury D . Sildenafil influences lower urinary tract symptoms. BJU Int. 2002; 90(9):836-9. DOI: 10.1046/j.1464-410x.2002.03040.x. View

McConnell J, Roehrborn C, Bautista O, Andriole Jr G, Dixon C, Kusek J . The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003; 349(25):2387-98. DOI: 10.1056/NEJMoa030656. View

Lepor H . Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998; 51(6):892-900. DOI: 10.1016/s0090-4295(98)00126-5. View

Roehrborn C, Boyle P, Nickel J, Hoefner K, Andriole G . Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002; 60(3):434-41. DOI: 10.1016/s0090-4295(02)01905-2. View

10.

Rosen R, Altwein J, Boyle P, Kirby R, Lukacs B, Meuleman E . Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003; 44(6):637-49. DOI: 10.1016/j.eururo.2003.08.015. View

11.

Nehra A, Steers W, Althof S, Andersson K, Burnett 2nd A, Costabile R . Third International Conference on the Management of Erectile Dysfunction: Linking Pathophysiology and Therapeutic Response. J Urol. 2003; 170(2 Pt 2):S3-5. DOI: 10.1097/01.ju.0000075566.73330.90. View

12.

Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U . Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res. 2001; 12(6):305-11. DOI: 10.1038/sj.ijir.3900622. View

13.

Namasivayam S, Minhas S, Brooke J, Joyce A, Prescott S, Eardley I . The evaluation of sexual function in men presenting with symptomatic benign prostatic hyperplasia. Br J Urol. 1999; 82(6):842-6. DOI: 10.1046/j.1464-410x.1998.00868.x. View

14.

Girman C, Jacobsen S, Tsukamoto T, Richard F, Garraway W, Sagnier P . Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology. 1998; 51(3):428-36. DOI: 10.1016/s0090-4295(97)00717-6. View

15.

Narayan P, Lepor H . Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology. 2001; 57(3):466-70. DOI: 10.1016/s0090-4295(00)01042-6. View

16.

Lue T . Erectile dysfunction. N Engl J Med. 2000; 342(24):1802-13. DOI: 10.1056/NEJM200006153422407. View

17.

Uckert S, Kuthe A, Stief C, Jonas U . Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. World J Urol. 2001; 19(1):14-22. DOI: 10.1007/pl00007090. View

18.

Gresser U, Gleiter C . Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature. Eur J Med Res. 2002; 7(10):435-46. View

19.

Burnett A, Maguire M, Chamness S, Ricker D, Takeda M, Lepor H . Characterization and localization of nitric oxide synthase in the human prostate. Urology. 1995; 45(3):435-9. DOI: 10.1016/S0090-4295(99)80012-0. View

20.

Johannes C, Araujo A, Feldman H, Derby C, Kleinman K, McKinlay J . Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000; 163(2):460-3. View